Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.91 |
| ▸ | CTSL | P07711 | 7/20 | 0.91 |
| ▸ | CTSV | O60911 | 6/20 | 0.91 |
| ▸ | CTSK | P43235 | 8/20 | 0.66 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677334 | 1.00 | CTSS (0.91) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL6799400 | 1.00 | CTSS (0.91) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL13677398 | 1.00 | CTSS (0.91) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL12392025 | 0.95 | CTSS (1.00) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL6802656 | 0.95 | CTSS (1.00) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL4456179 | 0.95 | CTSS (1.00) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL6808998 | 0.94 | CTSS (0.98) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL4452916 | 0.90 | CTSS (0.91) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL13677383 | 0.88 | CTSS (0.71) | CTSSCTSLCTSVCTSKCTSB | |
| SCHEMBL13677336 | 0.88 | CTSS (0.71) | CTSSCTSLCTSVCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSL 23/4885CTSV 27/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSS 21/4885CTSL 16/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.